Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Sylvia Rozek

Sports Medicine Durango, CO Medical Doctor

NPI 1104071588 CMS profile 1279500

1 Mercado St Ste 202, Durango, CO 81301

Open in the dashboard

General payments

$2,110

34 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sylvia Rozek of Durango, CO is reported in the CMS Open Payments database as having received $2,110 across 34 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $296 6
2024 General $1,525 11
2023 General $16 1
2022 General $38 2
2021 General $188 12
2020 General $47 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sylvia Rozek
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Sylvia Rozek were reported at $296. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Sylvia Rozek Sports Medicine median Middle half National median
2019 $0 $119 $35–$362 $163
2020 $47 $77 $24–$275 $114
2021 $188 $104 $28–$340 $132
2022 $38 $94 $31–$272 $149
2023 $16 $91 $34–$271 $160
2024 $1,525 $126 $38–$294 $164
2025 $296 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. TissueTech, Inc. $1,528 10 payments
  2. HydroCision, Inc. $159 3 payments
  3. Kerecis Limited $72 1 payment
  4. Bioventus LLC $65 3 payments
  5. Novo Nordisk Inc $52 3 payments
  6. Lilly USA, LLC $35 2 payments
  7. Avanos Medical $23 1 payment
  8. Amgen Inc. $22 1 payment
  9. Ferring Pharmaceuticals Inc. $20 1 payment
  10. DePuy Synthes Sales Inc. $19 1 payment
  11. Other $114 8 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Travel and Lodging $1,129 3 payments
  2. Food and Beverage $981 31 payments
Products named General payments · program years 2020–2025
  1. TENJET $159 3 payments
  2. Kerecis Omega3 SurgiClose $72 1 payment
  3. Kerecis Omega3 Marigen Wound Care $72 1 payment
  4. Kerecis Omega3 GraftGuide $72 1 payment
  5. Kerecis Omega3 Marigen Wound Care $72 1 payment
  6. Kerecis Omega3 Marigen Wound Care $72 1 payment
  7. RYBELSUS $52 3 payments
  8. Ozempic $52 3 payments
  9. Exogen Ultrasound Bone Healing System $28 1 payment
  10. ON-Q* PUMP AND ACCESSORIES $23 1 payment
  11. Other $327 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

1,145

Median for Sports Medicine: 144

Drug cost

$230,872

Median for Sports Medicine: $1,027

Branded share of claims

94.1%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 426 $89,936
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 256 $77,058
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 170 $50,443
Boostrix Tdap Diphth,pertuss(Acell),tet Vac Brand 174 $11,325
Twinrix Hepatitis A And B Vaccine/Pf Brand 12 $1,705
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 39 $178
Methylprednisolone Generic 17 $113
Meloxicam Generic 38 $101
Tramadol Hcl Generic 13 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$160,516

Of which drugs: $59,243

Medicare patients

468

Average age 73

Services billed

9,470

271 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 53%
Osteoporosis 28%
Ischemic heart disease 21%
Diabetes 16%
Depression 16%
Chronic kidney disease 15%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, romosozumab-aqqg, 1 mg J3111 Office 17 3,780 $32,734
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 16 1,380 $6,387
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 102 228 $1,236
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 149 964 $703

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

34 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record